Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system

Autor:	Lee, Tsung-Ying, Chen, Hsuan-Ying, Chen, Tsai-Yun, Li, Sin-Syue, Fang, Wei-Tse, Wen, Yao-Chun, Lo, Yu-Wen, Ou, Huang-Tz
Zdroj:	The European Journal of Health Economics, 2020 Sep 01. 21(7), 1105-1116.
Databáze:	JSTOR Journals
Externí odkaz:	https://www.jstor.org/stable/45382027 Zobrazit plný text záznamu Full text from SpringerLink